[Multiple sclerosis : therapy update]

Area of Science:

• Neurology
• Immunology
• Clinical Therapeutics

Background:

• Multiple sclerosis (MS) remains a significant cause of disability in young adults.
• Therapeutic strategies for MS have seen considerable recent advancements.
• Improved understanding and patient care are transforming MS management.

Purpose of the Study:

• To highlight recent therapeutic progress in multiple sclerosis.
• To emphasize the importance of early treatment and specialized care.
• To discuss the achievement of no evidence of disease activity (NEDA) as a treatment goal.

Main Methods:

• Review of recent advancements in multiple sclerosis therapeutics.
• Analysis of the impact of new drugs and treatment rationales.
• Evaluation of multidisciplinary care models in specialized units.

Main Results:

• Therapeutic progress has considerably improved knowledge and patient care in MS.
• Early treatment in specialized centers is a key factor for success.
• Clinical and neuroradiological no evidence of disease activity (NEDA) is increasingly achievable.
• Patient follow-up and evolution have significantly improved with greater efficacy.

Conclusions:

• Recent therapeutic progress has substantially enhanced multiple sclerosis management.
• Achieving no evidence of disease activity (NEDA) is a more attainable goal.
• Specialized, multidisciplinary care and early intervention are crucial for improved patient outcomes.